Abstract
Noah R. Wolkowicz, Christie W. Musket, Erin D. Reilly, Mehmet Sofuoglu, R. Ross MacLean
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
2025
The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017
10.1016/j.drugalcdep.2020.108350 · 2021
Unresolved referenced work
2022
Opioid use disorder with chronic pain increases disease burden and service use
10.1037/ser0000607 · 2023
Comparison of opioid use disorder among male veterans and non-veterans: disorder rates, socio-demographics, co-morbidities, and quality of life
10.1111/ajad.12861 · 2019
Chronic pain among patients with opioid use disorder: results from electronic health records data
10.1016/j.jsat.2017.03.006 · 2017
The association of opioid use disorder and homelessness nationally in the veterans health administration
10.1016/j.drugalcdep.2021.108714 · 2021
Unemployment rate, opioids misuse and other substance abuse: quasi-experimental evidence from treatment admissions data
10.1186/s12888-020-02981-7 · 2021
Trends in opioid use disorder in the veterans health administration, 2005–2022
10.1001/jamanetworkopen.2024.51821 · 2024
Problem opioid use among US military veterans: prevalence, correlates, and psychiatric characteristics
10.1097/adm.0000000000001286 · 2024
Unresolved referenced work
2024
Unresolved referenced work
2021
Advancing the pain agenda in the veteran population
10.1016/j.anclin.2016.01.003 · 2016
The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the national epidemiologic survey on alcohol and related conditions-III
10.1007/s00127-016-1208-5 · 2016
Prevalence of substance misuse among US veterans in the general population
10.1111/ajad.12534 · 2017
Stepped care for opioid use disorder train the trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within veterans health administration facilities
10.1080/08897077.2020.1787299 · 2020
Strategies to improve access to care for patients with opioid use disorder
10.1177/10600280241273258 · 2025
Retention strategies for medications for opioid use disorder in adults: a rapid evidence review
10.1097/adm.0000000000000739 · 2021
Drug overdose deaths in the United States, 2003–2023
10.15620/cdc/170565 · 2024
Pharmacological and behavioral treatment of opioid use disorder
10.1176/appi.prcp.20180006 · 2019
The management of substance use disorders: synopsis of the 2021 U.S. Department of veterans affairs and U.S. Department of defense clinical practice guideline
10.7326/m21-4011 · 2022
Medications for opioid use disorder: bridging the gap in care
10.1016/s0140-6736(17)32893-3 · 2018
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
10.1136/bmj.j1550 · 2017
Unresolved referenced work
2020
Retention of patients in opioid substitution treatment: a systematic review
10.1371/journal.pone.0232086 · 2020
Meta-analysis of primary care delivered buprenorphine treatment retention outcomes
10.1080/00952990.2023.2251653 · 2023
Buprenorphine use and courses of care for opioid use disorder treatment within the veterans health administration
10.1016/j.drugalcdep.2023.109902 · 2023
Three-year retention in buprenorphine treatment for opioid use disorder nationally in the veterans health administration
10.1111/ajad.12553 · 2017
Unresolved referenced work
2022
Impact of treatment duration on mortality among veterans with opioid use disorder in the United States veterans health administration
10.1111/add.15574 · 2021
Buprenorphine maintenance treatment of opiate dependence: correlations between prescriber beliefs and practices
10.3109/10826084.2015.1089905 · 2016
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
10.1002/14651858.cd002207.pub4 · 2014
Does retention matter? Treatment duration and improvement in drug use
10.1046/j.1360-0443.2003.00354.x · 2003
Evaluating the optimal duration of medication treatment for opioid use disorder
10.1111/add.70211 · 2026
Medication treatment of opioid use disorder
10.1016/j.biopsych.2019.06.020 · 2020
Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: x the X waiver
10.1001/jamapsychiatry.2018.3685 · 2018
Changes in methadone take-home dosing before and after COVID-19
10.1016/j.jsat.2021.108552 · 2022
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
10.1016/j.dadr.2023.100133 · 2023
Application of the COM-B model to patient barriers and facilitators of retention in medication treatment for opioid use disorder in rural northeastern United States: a qualitative study
10.1016/j.ssmmh.2022.100151 · 2022
U.S. Military veteran perspectives on barriers and facilitators to medication treatment for opioid use disorder
10.1080/10826084.2025.2580518 · 2025
A general inductive approach for analyzing qualitative evaluation data
10.1177/1098214005283748 · doi-reference
Examining the effectiveness of gamification in mental health apps for depression: systematic review and meta-analysis
10.2196/32199 · doi-reference
The use of gamification and incentives in Mobile health apps to improve medication adherence: scoping review
10.2196/30671 · doi-reference
Gamification in apps and technologies for improving mental health and well-being: systematic review
10.2196/13717 · doi-reference
Adoption of Mobile apps for depression and anxiety: cross-sectional survey study on patient interest and barriers to engagement
10.2196/11334 · doi-reference
The national center for PTSD model for digital mental health: a public sector approach to development, evaluation, implementation, and optimization of resources for helping trauma survivors
10.1037/tra0001838 · doi-reference
Availability and quality of mobile health app privacy policies
10.1136/amiajnl-2013-002605 · doi-reference
Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown
10.1186/s13722-022-00296-4 · doi-reference
Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups
10.1093/intqhc/mzm042 · doi-reference
Thematic analysis and its reconceptualization as ’saliency analysis’
10.1258/jhsrp.2009.009081 · doi-reference
Qualitative methods in implementation research: an introduction
10.1016/j.psychres.2019.112516 · doi-reference
Sample size in qualitative research
10.1002/nur.4770180211 · doi-reference
Code saturation versus meaning saturation: how many interviews are enough?
10.1177/1049732316665344 · doi-reference
Sample sizes for saturation in qualitative research: a systematic review of empirical tests
10.1016/j.socscimed.2021.114523 · doi-reference
Sample size for qualitative research
10.1108/qmr-06-2016-0053 · doi-reference
Using the COM-B model and behaviour change wheel to develop a theory and evidence-based intervention for women with gestational diabetes (IINDIAGO)
10.1186/s12889-023-15586-y · doi-reference
The behaviour change wheel: a new method for characterising and designing behaviour change interventions
10.1186/1748-5908-6-42 · doi-reference
Patient-perceived usefulness of online electronic medical records: employing grounded theory in the development of information and communication technologies for use by patients living with chronic illness
10.1197/jamia.m1712 · doi-reference
Social disparities in internet patient portal use in diabetes: evidence that the digital divide extends beyond access
10.1136/jamia.2010.006015 · doi-reference
Good intentions are not enough: how informatics interventions can worsen inequality
10.1093/jamia/ocy052 · doi-reference
A smartphone application to support recovery from alcoholism: a randomized clinical trial
10.1001/jamapsychiatry.2013.4642 · doi-reference
A randomized clinical trial of smartphone self-managed recovery support services
10.1016/j.jsat.2020.108089 · doi-reference
Veterans’ attitudes toward smartphone app use for mental health care: qualitative study of rurality and age differences
10.2196/10748 · doi-reference
Mobile applications may be the future of veteran mental health support but do veterans know yet? A survey of app knowledge and use
10.1037/ser0000562 · doi-reference
Digital access among a national sample of currently and formerly homeless veterans in 2022
10.1177/14604582241276974 · doi-reference
Smartphone ownership, smartphone utilization, and interest in using mental health apps to address substance use disorders: literature review and cross-sectional survey study across two sites
10.2196/38684 · doi-reference
Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder
10.1080/00325481.2021.1884471 · doi-reference
Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic
10.1080/14737167.2021.1840357 · doi-reference
The cost-effectiveness of digital health interventions: a systematic review of the literature
10.3389/fpubh.2022.787135 · doi-reference
Veterans affairs and the department of defense mental health apps: a systematic literature review
10.1037/ser0000289 · doi-reference
Access, utilization, and interest in mHealth applications among veterans receiving outpatient care for PTSD
10.7205/milmed-d-14-00014 · doi-reference
Potential and pitfalls of Mobile mental health apps in traditional treatment: an Umbrella review
10.3390/jpm12091376 · doi-reference
Mobile health interventions for substance use disorders
10.1146/annurev-clinpsy-080822-042337 · doi-reference
Medications for opioid use disorder in the department of veterans affairs (VA) health care system: historical perspective, lessons learned, and next steps
10.1080/08897077.2018.1452327 · doi-reference
Treatment experiences among people who use opioids: a social ecological approach
10.1177/10497323221104315 · doi-reference
The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): a nationwide veterans health administration cohort study
10.1016/j.drugalcdep.2022.109678 · doi-reference
The effects of psychosocial services in substance abuse treatment
10.1001/jama.1993.03500150065028 · doi-reference
Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: a qualitative study
10.1016/j.jsat.2021.108353 · doi-reference